MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,COMTO	0000180814	46	F	0000180814
Ordering Phys				**DOB** 06/10/1966
Client Order # 0000180814	**Account Information**			**Report Notes**
Collected 03/14/2013 23:42	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 05/23/2013 11:34				

Test	Flag	Results	Unit	Reference Value	Perform Site*
COMT Genotype, Saliva		REPORTED 05/22/2013 14:48			
Reviewed by		Jennifer Herman			MCR
Catechol Methyltransferase Genotype					MCR

Homozygous COMT*1/*1. This individual is homozygous for the COMT*1 normal allele and has two copies of the gene encoding enzyme with normal activity. This genotype is defined as normal and is associated with the extensive metabolizer phenotype.
Direct polymorphism analysis for 472G>A and 304G>A is performed following PCR amplification. Direct DNA testing will not detect all the known mutations that result in decreased or inactive COMT. Absence of a detectable gene mutation or polymorphism does not rule out the possibility that a patient has an intermediate or poor metabolizer phenotype. Patients with an extensive or intermediate metabolizer genotype may have COMT enzyme activity inhibited by a variety of medications, or their metabolites. The following is a partial listing of drugs known to affect COMT activity as of the date of this report.

Drugs that undergo metabolism by COMT: Alpha-methyl DOPA,Apomorphine, Benserazide, Bitolterol, Dihydroxyphenylserine, Dobutamine, Dopamine, Epinephrine, 2-Hydroxyestrogens, 4-Hydroxyestogens, Isoetherine, Isoprenaline, Isoproterenal, Norepinephrine, Rimiterol. Co-administration may decrease the rate of elimination of other drugs metabolized by COMT.

Structurally modified drugs that are not metabolized by COMT: Albuterol, Metaproterenol, Methoxamine, Phenylephrine, Perbuterol, Terbutaline. Co-administration will not decrease the rate of metabolism of other drugs by COMT.

Drugs known to inhibit COMT activity: Entacapone, Tolcapone, Nitecapone. Dietary Components that inhibit COMT activity: Quercetin, Tea catechins. Co-administration will decrease the rate of metabolism of COMT metabolized drugs, increasing the possibility of toxicity, including heterozygous individuals.
Laboratory developed test.

MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,COMTO	0000180814	46	F	0000180814
Ordering Phys				**DOB** 06/10/1966
Client Order # 0000180814	**Account Information**			**Report Notes**
Collected 03/14/2013 23:42	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 05/23/2013 11:35				

Test	Flag	Results	Unit	Reference Value	Perform Site*

>> Accession 0000180814 - Continued From Previous Page <<
>> Do Not Discard <<

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director:

* Report times for Mayo performed tests are CST/CDT